We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacterial BarCodes and Agilent in Marketing Agreement

By HospiMedica staff writers
Posted on 17 Oct 2003
A reseller agreement has been announced by Agilent Technologies, Inc. (Palo Alto, CA, USA) and Bacterial BarCodes (Houston, TX, USA) under which Bacterial BarCodes will market the Agilent 2100 bioanalyzer as a key component of a new system called DiversiLab System.

The DiversiLab System will enable users in clinical epidemiology, food safety, and pharmaceutical research to rapidly track the source and spread of a bacterial infection or contamination. Bacterial BarCodes has developed a repetitive sequence-based polymerase chain reaction (rep-PCR)-based DNA fingerprinting technology that will be combined with the Agilent 2100 bioanalyzer and the LabChip and reagents of Caliper Technologies (Hopkinton, MA, USA) to create the DiversiLab System. The Agilent 2100 is a microfluidics-based system for analyzing RNA, DNA, proteins, and cell fluorescence. It performs automated quality control, sizing, and quantification of nucleic acids or proteins, and simple flow cytometric analyses, all on one platform.

"The Agilent 2100 bioanalyzer provides our DiversiLab System with a standardized, automated platform for sample analysis, enabling our customers to quickly and effectively respond to a microbial outbreak,” noted David McWilliams, CEO of Bacterial BarCodes.





Related Links:
Agilent Technologies
Bacterial BarCodes

New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
HPV Molecular Test
BD Onclarity HPV Assay

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
17 Oct 2003  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
17 Oct 2003  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
17 Oct 2003  |   Industry



PURITAN MEDICAL